Chronobiologically explored effects of Telmisartan

Clinical and Experimental Hypertension

Volumn 27, Issue 2-3, 2005, Pages 119-128

  Prikryl, Pavel ^a   Cornélissen, Germaine ^b   Neubauer, Jiri ^c   Prikryl Jr , Pavel ^a   Karpisek, Zdenek ^d   Watanabe, Yoshihiko ^e   Otsuka, Kuniaki ^e   Halberg, Franz ^b  

^a MASARYK UNIVERSITY   (Czech Republic)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^d Technology Institute   (Czech Republic)

^e TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Blood pressure; Chronodiagnosis; Chronotherapy; Circadian hyper amplitude tension (CHAT); Ejection fraction; Heart rate; Low dose aspirin; Micardis (Telmisartan)

Indexed keywords

ACETYLSALICYLIC ACID; CREATININE; TELMISARTAN;

ADULT; AROUSAL; BLOOD PRESSURE; CARDIOVASCULAR SYSTEM; CHRONOBIOLOGY; CHRONOTHERAPY; CIRCADIAN HYPERAMPLITUDE TENSION; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DISEASE CLASSIFICATION; DISEASE COURSE; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG POTENTIATION; FEMALE; HEART EJECTION FRACTION; HEART RATE; HUMAN; HYPERTENSION; INTERMETHOD COMPARISON; INTRARENAL RESISTIVE INDEX; LOW DRUG DOSE; MALE; PATIENT MONITORING; RANDOMIZED CONTROLLED TRIAL; STUDENT T TEST; SYSTOLIC BLOOD PRESSURE; VASCULAR RESISTANCE; WAKEFULNESS; WORLD HEALTH ORGANIZATION;

ADMINISTRATION, ORAL; ADULT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ASPIRIN; BENZIMIDAZOLES; BENZOATES; BLOOD PRESSURE; CIRCADIAN RHYTHM; CROSS-OVER STUDIES; CYCLOOXYGENASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HEART RATE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 16444383418     PISSN: 10641963     EISSN: None     Source Type: Journal    
DOI: 10.1081/CEH-200048733     Document Type: Conference Paper

References (37)

1. Cornélissen G, Schwartzkopff O, Halberg F, Otsuka K, Watanabe Y. 7-Day ambulatory monitoring for adults with hypertension and diabetes [letter]. Am J Kidney Dis 2001; 37:878.
2. Halberg F, Cornélissen G, Halberg J, Fink H, Chen C-H, Otsuka K, Watanabe Y, Kumagai Y, Syutkina EV, Kawasaki T, Uezono K, Zhao ZY, Schwartzkopff O. Circadian Hyper-Amplitude-Tension, CHAT: A disease risk syndrome of anti-aging medicine. J Anti-Aging Med 1998; 1:239-259.
3. Otsuka K, Cornélissen G, Halberg F, Oehlert G. Excessive circadian amplitude of blood pressure increases risk of ischemic stroke and nephropathy. J Med Eng Technol 1997; 21:23-30.
4. Shinagawa M, Kubo Y, Otsuka K, Ohkawa S, Cornélissen G, Halberg F. Impact of circadian amplitude and chronotherapy: relevance to prevention and treatment of stroke. Biomed Pharmacother 2001; 55(suppl 1):125-132.
5. Cavallini M, Halberg F, Cornélissen G, Enrichens F, Margarit C. Organ transplantation and broader chronotherapy with implantable pump and computer programs for marker rhythm assessment. J Control Release 1986; 3:3-13.
6. Neutel JM. Use of ambulatory monitoring to evaluate the selective angiotensin receptor antagonist, telmisartan, and other antihypertensive drugs. Blood Press Monit 2000; 5(suppl 1):S35-S40.
7. Kulbertus H. Pharma-clinics. Medication of the month. Telmisartan (Micardis). Rev Med Liège 2000; 55:57-60.
8. Teichholz LE, Kreulen T, Herman MV, Gorlin R. Problems in echocardiographic volume determinations: echocardiographic-angiographic correlations in the presence of absence of asynergy. Am J Cardiol 1976; 37:7-11.
9. Kolosova R. Dopplerovske vysetrení renálních tepen. Kardiol Rev 2001; 2:70-74.
10. Ripolles T, Aliaga R, Morote V, Lonjedo E, Delgado F, Martinez MJ, Vilar J. Utility of intrarenal Doppler ultrasound in the diagnosis of renal artery stenosis. Eur J Radiol 2001; 40:54-63.
11. Cornélissen G, Halberg F. Chronomedicine. In: Armitage P, Colton T, ed. Encyclopedia of Biostatistics. Vol. 1. Chichester, UK: J. Wiley, 1998:642-649.
12. Halberg F. Chronobiology. Annu Rev Physiol 1969; 31:675-725.
13. Güllner HG, Bartter FC, Halberg F. Timing antihypertensive medication. Lancet 1979; 2(8141):527.
14. Cornélissen G, Zaslavskaya RM, Kumagai Y, Romanov Y, Halberg F. Chronopharmacologic issues in space. J Clin Pharmacol 1994; 34:543-551.
15. Little J, Sanchez de la Pena S, Cornélissen G, Abramowitz P, Tuna N, Halberg F. Longitudinal chronobiologic Blood Press Monit for assessing the need and timing of antihypertensive treatment. Prog Clin Biol Res 1990; 3416:601-611.
16. Cornélissen G, Halberg F, Prikryl P, Dankova E, Siegelova J, Dusek J, International Womb-to-Tomb Chronome Study Group. Prophylactic aspirin treatment: the merits of timing. JAMA 1991; 266:3128-3129.
17. Hermida RC, Ayala D, Fernandez JR, Mojon A, Alonso I, Silva I, Ucieda R, Codesido J, Iglesias M. Administration time-dependent effects of aspirin in women at differing risk for preeclampsia. Hypertension 1999; 34(4 Part 2 suppl S):1016-1023.
18. Siegelova J, Cornélissen G, Dusek J, Prikryl P, Fiser B, Dankova E, Tocci A, Ferrazzani S, Hermida R, Bingham C, Hawkins D, Halberg F. Aspirin and the blood pressure and heart rate of healthy women. Policlinico (Chrono) 1995; 1(2):43-49.
19. Watanabe Y, Cornélissen G, Otsuka K, Siegelova J, Jancik J, Halberg F. Longitudinal ambulatory blood pressure monitoring for a sequential chronobiologic assessment of losartan effect. Scripta Med (Brno) 2002; 75:129-134.
20. Dahlof B, Devereux RB, Julius S, Kjeldsen SE, Beevers G, de Faire U, Fyhrquist F, Hedner T, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H. Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension. Hypertension 1998; 32:989-997.
21. Wilson TW, Lacourciere Y, Barnes CC. The antihypertensive efficacy of losartan and amlodipine assessed with office and ambulatory blood pressure monitoring. Canadian Cozaar Hyzaar Amlodipine Trial Study Group. CMAJ 1998; 159:469-476.
22. Farsang C, Garcia-Puig J, Niegowska J, Baiz AQ, Vrijens F, Bortman G. The efficacy and tolerability of losartan versus atenolol in patients with isolated systolic hypertension. Losartan ISH Investigators Group. J Hypertens 2000; 18:795-801.
23. Almazov VA, Shlyakhto EV, Konrady AO, Macsimova TA, Zaharov DV, Rudomanov OG. Correction of hypertensive cardiac remodeling: comparison of different antihypertensive therapies. Med Sci Monit 2000; 6:309-313.
24. Omvik P, Gerdts E, Myking OL, Lund-Johansen P. Long-term central hemodynamic effects at rest and during exercise of losartan in essential hypertension. Am Heart J 2000; 140:624-630.
25. Tedesco MA, Ratti G, Aquino D, Limongelli G, di Salvo G, Mennella S, Galzerano D, Iarussi D, Iacono A. Effects of losartan on hypertension and left ventricular mass: a long-term study. J Hum Hypertens 1998; 12:505-510.
26. Verdecchia P, Schillaci G, Reboldi GP, Sacchi N, Bruni B, Benemio G, Porcellati C. Long-term effects of losartan and enalapril, alone or with a diuretic, on ambulatory blood pressure and cardiac performance in hypertension: a case-control study. Blood Press Monit 2000; 5:187-193.
27. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359:995-1003.
28. Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristiansson K, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman J, Snapinn S. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359:1004-1010.
29. Levy PJ, Yunis C, Owen J, Brosnihan KB, Smith R, Ferrario CM. Inhibition of platelet aggregability by losartan in essential hypertension. Am J Cardiol 2000; 86:1188-1192.
30. Prasad A, Koh KK, Schenke WH, Mincemoyer R, Csako G, Fleischer TA, Brown M, Selvaggi TA, Quyyumi AA. Role of angiotensin II type 1 receptor in the regulation of cellular adhesion molecules in atherosclerosis. Am Heart J 2001; 142:248-253.
31. Sica DA, Halstenson CE, Gehr TW, Keane WF. Pharmacokinetics and blood pressure response of losartan in end-stage renal disease. Clin Pharmacokinet 2000; 38:519-526.
32. Manolis AJ, Grossman E, Jelakovic B, Jacovides A, Bernhardi DC, Cabrera WJ, Watanabe LA, Barragan J, Matadamas N, Mendiola A, Woo KS, Zhu JR, Mejia AD, Bunt T, Dumortier T, Smith RD. Effects of losartan and candesartan monotherapy and losartan/hydrochlorothiazide combination therapy in patients with mild to moderate hypertension. Losartan Trial Investigators. Clin Ther 2000; 22:1186-1203.
33. Monterroso VH, Rodriguez Chavez V, Carbajal ET, Vogel DR, Aroca Martinez GJ, Garcia LH, Cuevas JH, Lara Teran J, Hitzenberger G, Leao Neves P, Middlemost SJ, Dumortier T, Bunt AM, Smith RD. Use of ambulatory Blood Press Monit to compare antihypertensive efficacy and safety of two angiotensin II receptor antagonists, losartan and valsartan. Losartan Trial Investigators. Adv Ther 2000; 17:117-131.
34. Lozano JV, Llisterri JL, Aznar J, Redon J, Spanish Working Group. Losartan reduces microalbuminuria in hypertensive microalbuminuric type 2 diabetics. Nephrol Dial Transplant 2001; 16(suppl 1):85-89.
35. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861-869.
36. Bingham C, Arbogast B, Cornélissen Guillaume G, Lee JK, Halberg F. Inferential statistical methods for estimating and comparing cosinor parameters. Chronobiologia 1982; 9:397-439.
37. Hawkins DM. Self-starting CUSUM charts for location and scale. Statistician 1987; 36:299-315.